Core Viewpoint - Hite BioPharmaceutical Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy, accelerate overseas business development, and improve its international brand image [1][2]. Group 1: Reasons for Listing - The company aims to deepen its global strategic layout and enhance its overseas financing capabilities to support high-quality development [2]. - The listing is part of a strategy to create a diversified capital operation platform [2]. Group 2: Financial Performance - For the first three quarters of 2025, the company reported revenue of 422 million yuan, a year-on-year decrease of 6.45%, and a net profit attributable to shareholders of -158 million yuan, a decline of 297.78% [5]. - Hite Bio has experienced three consecutive years of losses, with revenues of 689 million yuan, 602 million yuan, and 649 million yuan from 2022 to 2024, reflecting year-on-year changes of 12.03%, -12.54%, and 7.75% respectively [5]. - The net profit attributable to shareholders for the same period was -14.03 million yuan, -121 million yuan, and -69.35 million yuan [5]. Group 3: Company Background - Hite Bio specializes in the production and sales of large molecule biopharmaceuticals, small molecule chemical drugs, raw materials, and pharmaceutical intermediates [4]. - The company provides CRO, CMO, and CDMO technical services for domestic and international pharmaceutical companies [4]. - Key products include Jinlujie, the world's first commercialized nerve growth factor new drug, and Epinavim (brand name: Shaite), a recombinant protein targeted anti-tumor new drug [4].